Just before turning the page to 2026, it’s worth pausing to reflect on both the progress made and the challenges that remain in the fight against antimicrobial resistance (AMR). The numbers, unfortunately, haven’t changed. According [...]
More news
The INCATE Selection Committee selected another 5 ventures for Stage I support in Q4 2022. [...]
The INCATE team is expanding and we have three positions open to join the INCATE [...]
Who invests in Antibiotics? What are they looking for? How do they help grow companies? [...]
We are excited to announce our comment highlighting the INCATE mission is now available in [...]
Six new ventures have been selected to join the INCATE portfolio. The six ventures reflect [...]
The first Entrepreneurs Club is on July 7th 5-6pm CEST. Magdalena Kempa, CEO Smartbax and [...]
Congratulations to LimmaTech Biologics AG for the AMR Conference prize We are very happy to [...]
The INCATE portfolio is now live at Portfolio More than a million people die because [...]
